This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study designs and other criteria for inclusion in the review
The only criteria reported by the author were articles on ACT in breast cancer. MEDLINE was searched between 1986 and 1998. Criteria used to ensure the validity of primary studies Not reported.
Sources searched to identify primary studies

Methods used to judge relevance and validity, and for extracting data
Not reported.
Number of primary studies included
A total of 778 articles citing the words "breast cancer" and "adjuvant chemotherapy" were initially included in the review.
Methods of combining primary studies
Sub-groups were identified from the initial studies identified. The author used data from three included studies for effectiveness (Fisher et al.) 
Investigation of differences between primary studies
Not investigated.
Results of the review
The following values were included as parameters of the model: 51 years gained per 100 women during the first 10 years of treatment; an improvement of 8.5% for survival among 10-year survivors; and a life expectancy of 22.8 years for 60-year-old Norwegian women.
In terms of quality of life, the author considered a decrease of 0.33 (0 -1 scales) for 6 months during therapy, and a quality of life of 0.86 following adjuvant CMF lasting for the rest of life.
Measure of benefits used in the economic analysis
The measures of benefits used were the life-years gained and the quality-adjusted life-years (QALYs).
Direct costs
The cost/resource boundary adopted was that of society. The broad expenditure areas included were drugs, administration and travel costs. The resource use data came from the University Hospital of Tromso, while the price data came from the National Health Administration and the Norwegian Price List. A discount rate of 5% was used. The quantities and the costs were reported separately. The price year was 1998.
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Statistical analysis of costs
The cost data were treated deterministically.
Indirect Costs
The human capital approach and the friction cost methods were used to measure productivity losses. The data came from Norway Statistics. The travel costs were obtained from a published study. A discount rate of 5% was used. The price year was 1996.
Currency
UK pounds sterling (). The conversion rate was Norwegian kroner 12 = 1.
Sensitivity analysis
Variability in the data was investigated. One-way sensitivity analyses were performed on drug prices (use of brandname products instead of generic products) and life expectancy.
Estimated benefits used in the economic analysis
The benefits were not reported separately in the paper, but are reflected in the synthesis of costs and benefits (see Synthesis of Costs and Benefits).
Cost results
The author reported undiscounted total costs for ACT with CMF of 2,365 (friction cost approach) and 6,253 (human capital approach).
Synthesis of costs and benefits
Incremental cost-effectiveness and cost-utility analyses were performed. The undiscounted incremental cost per lifeyear saved was 965 with the friction cost method and 2,552 with the human capital approach. When considering the effect of a 5% discount rate on both the benefits and costs, the results were estimated to be 2,170 and 5,737, respectively.
The undiscounted incremental cost per QALY was 1,218 with the friction cost method and 3,220 with the human capital approach. When considering the effect of a 5% discount rate on both the QALYs and costs, the results were reported to be 2,973 and 7,860, respectively.
